CG Oncology, Inc. Common stock (CGON)
CG Oncology, Inc. is a biotechnology company focused on developing targeted therapies for cancer treatment. The company leverages its proprietary antibody discovery platform to identify and develop novel immuno-oncology drugs aimed at improving patient outcomes in various cancer types.
Company News
Guggenheim initiated coverage on CG Oncology with a buy rating and $90 price target, highlighting the company's promising investigational drug for non-muscle invasive bladder cancer treatment.
CG Oncology reported promising 24-month results for cretostimogene, a potential bladder cancer treatment, showing a 41.8% complete response rate in high-risk non-muscle invasive bladder cancer patients unresponsive to previous treatments.
9 analysts have expressed a variety of opinions on CG Oncology (NASDAQ:CGON) over the past quarter, offering a diverse set of opinions from bullish to bearish. The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewha...
One way to find potentially winning stocks to buy in March, April, and throughout the year is to search for companies gaining more attention from Wall Street analysts.
Venture-capital firms faced with challenge of returning capital to their investors.